BioLamina Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 120

Employees

  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $23.2M

  • Investors
  • 6

BioLamina General Information

Description

Developer of cell culture reagents designed to imitate the natural, cell-specific matrix interaction. The company's reagents provide assistance in culturing primary cells, preparing antibiotics, and cell development tools, such as stem cells, enabling doctors to achieve clinically compliant cell therapies and research outcomes to improve cell functionality.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Lofstroms Alle 5 A
  • 172 66 Sundbyberg
  • Sweden
+46 08-588
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Lofstroms Alle 5 A
  • 172 66 Sundbyberg
  • Sweden
+46 08-588

BioLamina Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioLamina Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Debt - General 16-Apr-2026 $23.2M Completed Generating Revenue
7. Later Stage VC 12-Sep-2023 Completed Generating Revenue
6. Later Stage VC 31-Dec-2021 Completed Generating Revenue
5. Later Stage VC 31-Dec-2020 Completed Generating Revenue
4. Secondary Transaction - Private Completed Generating Revenue
3. Grant 07-Nov-2018 Completed Generating Revenue
2. Later Stage VC 01-Jan-2017 $1.19M $3.52M Completed Generating Revenue
1. Later Stage VC 13-Nov-2013 $2.32M $2.32M Completed Generating Revenue
To view BioLamina’s complete valuation and funding history, request access »

BioLamina Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
Preference
Preference
Preference
Preference 19,400 $68.04 $68.04 1x $68.04 8.36%
Preference 13,774 $136.89 $136.89 1x $136.89 5.94%
To view BioLamina’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

BioLamina Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell culture reagents designed to imitate the natural, cell-specific matrix interaction. The company's reag
Biotechnology
Sundbyberg, Sweden
120 As of 2026

Cranbury, NJ
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioLamina Competitors (10)

One of BioLamina’s 10 competitors is PeproTech, a Corporate Backed or Acquired company based in Cranbury, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PeproTech Corporate Backed or Acquired Cranbury, NJ
Cardiff Oncology Formerly Angel backed San Diego, CA
Illumina Formerly VC-backed San Diego, CA
Meridian Bioscience Private Equity-Backed Cincinnati, OH
Proteintech Corporation Rosemont, IL
You’re viewing 5 of 10 competitors. Get the full list »

BioLamina Patents

BioLamina Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3810758-A1 Methods and compositions for producing retinal pigment epithelium cells Active 20-Jun-2018
EP-3810758-B1 Methods and compositions for producing retinal pigment epithelium cells Active 20-Jun-2018
EP-4234024-A2 Methods and compositions for producing retinal pigment epithelium cells Active 20-Jun-2018
EP-4234024-A3 Methods and compositions for producing retinal pigment epithelium cells Active 20-Jun-2018
EP-4234024-B1 Methods and compositions for producing retinal pigment epithelium cells Active 20-Jun-2018 C12N5/0621
To view BioLamina’s complete patent history, request access »

BioLamina Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioLamina Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Lauxera Capital Partners Growth/Expansion Minority
Northislet Growth/Expansion Minority
Vinnova Government
Zentrales Innovationsprogramm Mittelstand Government
Bure Equity PE/Buyout Minority
You’re viewing 5 of 6 investors. Get the full list »

BioLamina FAQs

  • When was BioLamina founded?

    BioLamina was founded in 2008.

  • Where is BioLamina headquartered?

    BioLamina is headquartered in Sundbyberg, Sweden.

  • What is the size of BioLamina?

    BioLamina has 120 total employees.

  • What industry is BioLamina in?

    BioLamina’s primary industry is Biotechnology.

  • Is BioLamina a private or public company?

    BioLamina is a Private company.

  • What is BioLamina’s current revenue?

    The current revenue for BioLamina is .

  • How much funding has BioLamina raised over time?

    BioLamina has raised $50.2M.

  • Who are BioLamina’s investors?

    Lauxera Capital Partners, Northislet, Vinnova, Zentrales Innovationsprogramm Mittelstand, and Bure Equity are 5 of 6 investors who have invested in BioLamina.

  • Who are BioLamina’s competitors?

    PeproTech, Cardiff Oncology, Illumina, Meridian Bioscience, and Proteintech are some of the 10 competitors of BioLamina.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process